PortViewPortView
Evolus logo

Evolus (EOLS) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$8.96-1.28%
1-year price historyRange $3.94 – $9.09
52-week range$8.96
$3.86$9.15

What Evolus does

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Key metrics

Market cap
$590.30M
P/E (TTM)
-28.39
EPS (TTM)
$-0.32
Beta
1.36
Dividend yield
0.00%
Revenue / share
$4.80
50-day avg
$7.14
200-day avg
$6.03
52-week high
$9.15
52-week low
$3.86
CEO
David Moatazedi

ETFs linked to EOLS

Broad-market and Healthcare sector ETFs an investor holding Evolus is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EOLS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze EOLS in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Evolus?
Evolus trades under the ticker EOLS on NASDAQ.
Which exchange is EOLS listed on?
EOLS is listed on NASDAQ.
What sector does Evolus operate in?
Evolus is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze EOLS in a portfolio?
PortView shows EOLS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.